de BlackRock Lexicon Pharmaceuticals LXRX Historial de posiciones en acciones
Compró
Mantenido
Vendió
| Trimestre | Valor de mercado | Estado | Núm. de acciones |
Cambio en la participación | Valor operado | Peso en el portafolio | Posición de la cartera | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | USD 41.6 M | Comprar |
17,348,741
+14,026,522
| +422% | +USD 27.3 M | ﹤0.01% | 2791 |
|
|
2026
Q1 | USD 5.18 M | Comprar |
3,322,219
+129,771
| +4% | +USD 189 k | ﹤0.01% | 3819 |
|
|
2025
Q4 | USD 3.67 M | Vender |
3,192,448
-202,524
| -6% | -USD 278 k | ﹤0.01% | 3941 |
|
|
2025
Q3 | USD 4.58 M | Comprar |
3,394,972
+40,303
| +1% | +USD 45.7 k | ﹤0.01% | 3812 |
|
|
2025
Q2 | USD 3.17 M | Vender |
3,354,669
-6,658,338
| -66% | -USD 4.31 M | ﹤0.01% | 3937 |
|
|
2025
Q1 | USD 4.61 M | Vender |
10,013,007
-320,151
| -3% | -USD 202 k | ﹤0.01% | 3677 |
|
|
2024
Q4 | USD 7.63 M | Comprar |
10,333,158
+200,144
| +2% | +USD 241 k | ﹤0.01% | 3553 |
|
|
2024
Q3 | USD 15.9 M | Comprar |
10,133,014
+242,861
| +2% | +USD 433 k | ﹤0.01% | 3175 |
|
|
2024
Q2 | USD 16.6 M | Comprar |
9,890,153
+2,196,876
| +29% | +USD 3.94 M | ﹤0.01% | 3088 |
|
|
2024
Q1 | USD 18.5 M | Comprar |
7,693,277
+688,124
| +10% | +USD 1.48 M | ﹤0.01% | 3035 |
|
|
2023
Q4 | USD 10.7 M | Comprar |
7,005,153
+350,187
| +5% | +USD 416 k | ﹤0.01% | 3363 |
|
|
2023
Q3 | USD 7.25 M | Comprar |
6,654,966
+275,780
| +4% | +USD 484 k | ﹤0.01% | 3505 |
|
|
2023
Q2 | USD 14.6 M | Comprar |
6,379,186
+722,259
| +13% | +USD 1.92 M | ﹤0.01% | 3220 |
|
|
2023
Q1 | USD 13.7 M | Vender |
5,656,927
-195,558
| -3% | -USD 448 k | ﹤0.01% | 3158 |
|
|
2022
Q4 | USD 11.2 M | Comprar |
5,852,485
+92,485
| +2% | +USD 197 k | ﹤0.01% | 3345 |
|
|
2022
Q3 | USD 13.8 M | Comprar |
5,760,000
+1,240,171
| +27% | +USD 3.43 M | ﹤0.01% | 3248 |
|
|
2022
Q2 | USD 8.41 M | Comprar |
4,519,829
+74,077
| +2% | +USD 141 k | ﹤0.01% | 3594 |
|
|
2022
Q1 | USD 9.29 M | Vender |
4,445,752
-102,172
| -2% | -USD 283 k | ﹤0.01% | 3616 |
|
|
2021
Q4 | USD 17.9 M | Vender |
4,547,924
-102,746
| -2% | -USD 499 k | ﹤0.01% | 3338 |
|
|
2021
Q3 | USD 22.4 M | Comprar |
4,650,670
+3,811
| +0.1% | +USD 15.6 k | ﹤0.01% | 3208 |
|
|
2021
Q2 | USD 21.3 M | Comprar |
4,646,859
+742,712
| +19% | +USD 3.58 M | ﹤0.01% | 3256 |
|
|
2021
Q1 | USD 22.9 M | Comprar |
3,904,147
+970,186
| +33% | +USD 6.72 M | ﹤0.01% | 3114 |
|
|
2020
Q4 | USD 10 M | Vender |
2,933,961
-967,183
| -25% | -USD 1.84 M | ﹤0.01% | 3356 |
|
|
2020
Q3 | USD 5.62 M | Vender |
3,901,144
-315,828
| -7% | -USD 562 k | ﹤0.01% | 3520 |
|
|
2020
Q2 | USD 8.41 M | Comprar |
4,216,972
+195,227
| +5% | +USD 383 k | ﹤0.01% | 3284 |
|
|
2020
Q1 | USD 7.84 M | Vender |
4,021,745
-32,889
| -0.8% | -USD 97.9 k | ﹤0.01% | 3119 |
|
|
2019
Q4 | USD 16.8 M | Vender |
4,054,634
-89,309
| -2% | -USD 344 k | ﹤0.01% | 2977 |
|
|
2019
Q3 | USD 12.5 M | Comprar |
4,143,943
+84,385
| +2% | +USD 261 k | ﹤0.01% | 3106 |
|
|
2019
Q2 | USD 25.5 M | Vender |
4,059,558
-71,964
| -2% | -USD 431 k | ﹤0.01% | 2708 |
|
|
2019
Q1 | USD 23 M | Vender |
4,131,522
-225,204
| -5% | -USD 1.37 M | ﹤0.01% | 2675 |
|
|
2018
Q4 | USD 28.9 M | Vender |
4,356,726
-50,915
| -1% | -USD 412 k | ﹤0.01% | 2531 |
|
|
2018
Q3 | USD 47 M | Vender |
4,407,641
-14,652
| -0.3% | -USD 168 k | ﹤0.01% | 2408 |
|
|
2018
Q2 | USD 53.1 M | Comprar |
4,422,293
+195,461
| +5% | +USD 2 M | ﹤0.01% | 2331 |
|
|
2018
Q1 | USD 36.2 M | Vender |
4,226,832
-129,076
| -3% | -USD 1.19 M | ﹤0.01% | 2450 |
|
|
2017
Q4 | USD 43 M | Vender |
4,355,908
-475,745
| -10% | -USD 4.94 M | ﹤0.01% | 2382 |
|
|
2017
Q3 | USD 59.4 M | Comprar |
4,831,653
+172,524
| +4% | +USD 2.55 M | ﹤0.01% | 2182 |
|
|
2017
Q2 | USD 76.6 M | Vender |
4,659,129
-199,361
| -4% | -USD 3.09 M | ﹤0.01% | 1977 |
|
|
2017
Q1 | USD 69.7 M | Comprar |
4,858,490
+4,841,782
| +28,979% | +USD 71.8 M | ﹤0.01% | 2021 |
|
|
2016
Q4 | USD 231 k | Vender |
16,708
-2,224
| -12% | -USD 35.7 k | ﹤0.01% | 2053 |
|
|
2016
Q3 | USD 342 k | Comprar |
18,932
+15,661
| +479% | +USD 252 k | ﹤0.01% | 1885 |
|
|
2016
Q2 | USD 47 k | Vender |
3,271
-1,462
| -31% | -USD 19.8 k | ﹤0.01% | 2964 |
|
|
2016
Q1 | USD 57 k | Comprar |
4,733
+3,778
| +396% | +USD 39.6 k | ﹤0.01% | 2299 |
|
|
2015
Q4 | USD 13 k | Comprar |
955
+57
| +6% | +USD 701 | ﹤0.01% | 2763 |
|
|
2015
Q3 | USD 10 k | Mantener |
898
| – | – | ﹤0.01% | 2727 |
|
|
2015
Q2 | USD 7 k | Mantener |
898
| – | – | ﹤0.01% | 2990 |
|
|
2015
Q1 | USD 6 k | Mantener |
898
| – | – | ﹤0.01% | 2976 |
|
|
2014
Q4 | USD 6 k | Mantener |
898
| – | – | ﹤0.01% | 3005 |
|
|
2014
Q3 | USD 9 k | Comprar |
898
+178
| +25% | +USD 1.9 k | ﹤0.01% | 2792 |
|
|
2014
Q2 | USD 8 k | Vender |
720
-140
| -16% | -USD 1.5 k | ﹤0.01% | 2927 |
|
|
2014
Q1 | USD 10 k | Mantener |
860
| – | – | ﹤0.01% | 2706 |
|
|
2013
Q4 | USD 11 k | Mantener |
860
| – | – | ﹤0.01% | 2661 |
|
|
2013
Q3 | USD 14 k | Mantener |
860
| – | – | ﹤0.01% | 2443 |
|
|
2013
Q2 | USD 13 k | Comprar |
+860
| Nuevas | +USD 13.1 k | ﹤0.01% | 2503 |
|
Otros fondos que tienen LXRX en su cartera
AG
SL
Posición de BlackRock en LXRX: resumen de T2 2026
BlackRock aumentó su participación en Lexicon Pharmaceuticals (LXRX) en 422% durante T2 2026, al comprar aproximadamente USD 27.3 M y elevar la posición a 17,348,741 acciones con un valor de USD 41.6 M. La posición representa ﹤0.01% de la cartera y ocupa el puesto #2791.
BlackRock reportó por primera vez una posición en LXRX en T2 2013 y la ha mantenido durante 53 trimestres desde entonces. La posición alcanzó su máximo de USD 76.6 M en T2 2017. Al cierre de T2 2026, 149 fondos que sigue Wall St. Rank mantienen una posición en LXRX.
- Al cierre de T2 2026, BlackRock tenía 17,348,741 acciones de Lexicon Pharmaceuticals con un valor de USD 41.6 M.
- BlackRock compró 14,026,522 acciones de Lexicon Pharmaceuticals en T2 2026, por un monto estimado de USD 27.3 M.
- Lexicon Pharmaceuticals representó ﹤0.01% de la cartera de BlackRock en T2 2026 y fue su posición número 2791.
- BlackRock reportó por primera vez una posición en Lexicon Pharmaceuticals en T2 2013 y la ha mantenido durante 53 trimestres desde entonces.
- La posición de BlackRock en Lexicon Pharmaceuticals alcanzó su máximo de USD 76.6 M en T2 2017.
- Al cierre de T2 2026, 149 fondos que sigue Wall St. Rank tenían Lexicon Pharmaceuticals en cartera.
Según el Informe 13F de BlackRock correspondiente a T2 2026, presentado el 7 ago 2026.